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Background. Panton-Valentine leukocidin (PVL-)producing Staphylococcus aureus is emerging as a serious problem worldwide.
There has been an increase in the incidence of necrotizing lung infections in otherwise healthy young people with a very high
mortality associated with these strains. Sporadic severe infectious complications after incision of Bartholin’s abcesses have been
described but involvement of S. aureus is rare. Case report. We present a 23-year-old apparently healthy female patient without any
typicalpredisposingﬁndingswhodevelopedseveresepsiswithnecrotizingpneumoniaandmultipleabscessesfollowingincisionof
a Bartholin’s abscess. Methicillin-sensitive S. aureus harbouring Panton-Valentine leucocidin genes were cultured from the abscess
ﬂuid, multiple blood cultures and a postoperative wound swab. Aggressive antibiotic therapy with ﬂucloxacillin, rifampicin and
clindamycin, drainage and intensive supportive care lead ﬁnally to recovery. Conclusions. S. aureus, in particular PVL-positive
strains, should be considered when a young, immunocompetent person develops a fulminant necrotizing pneumonia. Minor
infections—such as Bartholin’s abscess—can precede this life-threating syndrome. Bactericidal antistaphylococcal antibiotics are
recommended for treatment, and surgical procedures may become necessary.
Copyright © 2008 N. Jung et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Panton-Valentine leucocidin (PVL) is a pore-forming cyto-
toxin of Staphylococcus aureus inducing leukocyte lysis. It has
been associated with diverse clinical syndromes, including
primary and secondary skin infections such as furunculosis
and abscesses and deep seated infections such as necrotizing
pneumonia. Its role and regulation are still under investiga-
tion [1]. S. aureus has the capacity to produce a wide array of
virulence factors which are responsible for divergent clinical
syndromes [2]. In the US, the most common circulating
community-associated methicillin-resistant S. aureus strain
USA 300 contains PVL, but most infections are skin and soft
tissue infections, including boils, and are not life threatening
[3].
Necrotizing pneumonia due to PVL-positive S. aureus
is usually severe and often fatal, involves primarily young
and healthy patients, and carries a mortality rate up to 75%
despite intensive medical treatment [4].
To our knowledge, we present the ﬁrst case of necrotizing
pneumonia following incision of a Bartholin’s abscess. In
October 2006, a 23-year-old woman with no systemic signs
of infection had a surgical incision of a Bartholin’s abscess
(3 × 5 × 3cm) without the installation of a drainage. The
patient was discharged without antimicrobial therapy. The
abscess ﬂuid was submitted for culture.
24 hours later, the woman developed fever and her state
of health worsened continuously, so she was admitted to
a local hospital 4 days after surgery. Community-acquired
pneumonia was diagnosed and a macrolide was adminis-
tered. One day later, the patient became critically ill and
was transferred to our tertiary care hospital and immediately
admitted to the intensive care unit.
She presented with an inﬂuenza-like illness with severe
muscle pain in all extremities, spiking fever up to 40◦C,
dry cough but no sore throat. She showed ortho- and2 Infectious Diseases in Obstetrics and Gynecology
Figure 1: CT scan revealed nodular opacities and diﬀuse bilateral
inﬁltrates.
tachypnoea with a respiratory rate of 30 breaths/minute,
oxygen saturation was 96% with the supply of 31/minute
of oxygen but no need for intubation. Her blood pressure
was 100/60mmHg and her heart rate 140/minute. Physical
examination revealed crackles in the inferior and middle
parts of both lungs, a diﬀuse tenderness of the abdomen,
and severe pain in the muscles. Auscultation of the heart was




count of 13.6 × 109/L, a very low platelet count of 24 ×
109/L, elevated inﬂammatory markers including a C-reactive
protein of 399mg/L (reference range (RR) < 5mg/L) and
a procalcitonin level of 34ng/L (RR < 0.1ng/L), and
an elevated creatinine of 1.27mg/dl. Her hemoglobin was
only slightly reduced with 11.5g/dl. As the patient did not
present during the inﬂuenza season and ﬁrst occurence of
the inﬂuenza-like symptoms was parallel with the positive
blood cultures, testing was not performed. Testing for HIV
was negative and fasting glucose was normal. As the patient
had no increased rateof infections in thepast, we did not test
for complement of IgG deﬁciency. Multiple blood cultures
and swabs of the postoperative wound and the vagina were
obtained and sumitted for culture.
A computed tomography scan (CT) of the chest showed
diﬀuse bilateral alveolar inﬁltrates and nodular opacities
with cavity forming consistent with necrotising pneumonia
(Figure 1).
Transthoracal echocardiography on the day after admis-
sion showed no abnormal ﬁndings, in particular no veg-
etations suggestive of infective endocarditis. Community-
onset pneumonia and severe sepsis with coagulopathy was
diagnosed.
Empirical intravenous antibiotic therapy with pipera-
cillin/tazobactam and levoﬂoxacin was started immediately.
On day 2, the initial abscess ﬂuid yielded S. aureus fully
susceptibletoantistaphylococcalagentswiththeexceptionof
penicillinandtetracyclin.Therefore,piperacillin/tazobactam
was changed to high-dose intravenous ﬂucloxacillin 4g tid
and levoﬂoxacin was discontinued. On day 3, blood cultures
and both wound and vaginal swab taken on admission also
grew S. aureus. On day 4, rifampicin 600mg Rifampicin
600 mg (once daily) was added as blood cultures continued
to be positive and the patient still suﬀered from high
fever and severe dyspnoea. CT scans of the chest and
abdomen showed newly emerged extensive bilateral pleural
eﬀusions. In addition, multiple abscesses had evolved in the
pectoralis,supraspinatus,andgluteusmuscle.Areevaluation
of the heart valves by transesophagal echocardiography
revealed no abnormalities. On day 6, polymerase chain
reaction (PCR) ampliﬁcation of the lukS-lukF genes was
performed as described previously [5] and conﬁrmed the
presence of the PVL gene in all available S. aureus isolates.
Subsequently, clindamyin 600mg tid was added on day 7.
With this treatment, blood cultures became negative on day
8. On day 11, bilateral pleural drainage tubes had to be
inserted as eﬀusions increased. Cultures of the pleural ﬂuid
showed no growth. All S. aureus isolates from the abscess,
the postoperative wound and multiple blood cultures had
identical susceptibility proﬁles. Minimal inhibitory concen-
trations (MICs) were <0.25mg/l for oxacillin, <0.25mg/l for
clindamycin, and <0.5mg/l for rifampicin. Pulsed-ﬁeld gel
electrophoresis (PFGE) of SmaI digests of genomic DNA
from all available S. aureus isolates showed identical patterns
(data not shown).
The patient recovered very slowly with a 3 weeks
stay at the intensive care unit with maximal supportive
care. Respiratory support and vasopressors had not been
necessary. Subsequently, the patient stayed for another 8
weeks on a regular ward until recovery. Antibiotics were
continued for a total treatment duration of 5 weeks for
rifampicin and clindamycin and of 8 weeks for ﬂucloxacillin.
Swabs of persons in close contact to the patient were
taken but were negative for PVL-producing S. aureus.
S. aureus is a major cause of respiratory, skin, bone, joint,
and endovascular infections. Mostly these infections occur
in persons with known risk factors such as cardiovascular
disease, malignancy, or diabetes mellitus. S. aureus is respon-
sible for at least 10% of cases of nosocomial pneumonia but
only for 2% of community-acquired pneumonia [6, 7].
Our patient was a young immunocompetent woman
with no apparent risk factors who sustained severe commu-
nity-onset necrotizing pneumonia, multiple abscesses, and
extensive pleural eﬀusions. These clinical features are char-
acteristic for invasive infections with S. aureus exhibiting the
putative virulence factor PVL.
The true incidence of PVL-associated pneumonia is
unknown, since the number of cases published is likely to
be an underestimate. Besides its occurence in methicillin-
sensitive S. aureus (MSSA), PVL is more often identiﬁed in
community-acquired methicillin-resistant S. aureus (MRSA)
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PVL is a very virulent toxin expressed by S. aureus,
which was ﬁrst characterized in 1932. Less than 5% of all
S. aureus strains harbor PVL genes. PVL is a pore-forming
toxin destroying the membrane of the host defence cells and
erythrocytes [9]. Lina et al. [5]s c r e e n e dS. aureus isolates to
correlate toxin production with disease manifestation. They
found a deﬁnite association between the occurrence of PVL
genes and furunculosis and community-onset pneumonia.
Gilletetal.[4]comparedtheclinicalfeaturesofPVL-positive
pneumonia with PVL-negative pneumonia and found sig-
niﬁcant diﬀerences. PVL-positive patients were younger
without risk factors for infection. They presented more often
with haemoptysis, high fever, tachycardia, tachypnoea and
developed diﬀuse bilateral inﬁltrates and pleural eﬀusion.
The mortality rate was signiﬁcantly higher with 75% in
PVL-positive compared to 47% in PVL-negative infections.
Other case series conﬁrm the characteristics and severeness
ofthePVL-positiveinfections[10–14].Thesymptomsofour
patient ﬁtted very well into this disease.
Since PVL-positive S. aureus strains may spread between
persons in close contact to the index patient [15], swabs
should be taken to prevent further spreading. In a report
from Germany, control of a furunculosis outbreak involving
PVL-positive MSSA in a rural village was achieved by
stringent decolonization of carriers [16], but established
public health recommendations do not exist.
For the therapy of necrotizing pneumonia caused by
PVL-positive S. aureus no speciﬁc guidelines have been
published. Combination therapy is widely used empirically
in life-threatening infections. Bactericidal antibiotics such as
β-lactam antibiotics are preferrd over bacteriostatic agents.
For pneumonia, good penetration into the tissue has also
to be considered. We added levoﬂoxacin empirically to
piperacillin/tazobactam to treat potential atypical bacteria.
As soon as cultures became positive for S. aureus the antibi-
otic regimen was changed from piperacillin/tazobactam to
high-dose ﬂucloxacillin, as this is the antibiotic of choice for
β-lactamase-positive S. aureus. As blood cultures remained
continuously positive and the patient’s condition wors-
ened, rifampicin, another very potent antistaphylococcal
antibiotic, was added. The eﬃcacy of rifampicin as an
adjunctive drug in patients with life-threatening infections
remains controversial. As soon as the S. aureus isolates
turned out to be PVL-positive, clindamycin was added.
Several authors recommend the addition of clindamycin
to the treatment of toxin-producing grampositive bacteria
as it targets the bacterial ribosomes thereby potentially
blocking the toxin production [17, 18]. New in vitro data
showed an augmentation of PVL toxin production by β-
lactam antibiotics, but no in vivo data have supported these
observations so far [19, 20]. Other in vitro data showed
that the addition of rifampicin or clindamycin to oxacillin
inhibits PVL production [21]. PVL-positive MRSA infection
requires treatment with vancomycin as the ﬁrst-line agent.
In severe S. aureus infections intravenous antibiotic therapy
shouldbegivenforatleast4weeksafterthelastbloodculture
positive for S. aureus . Although PVL plays a key role in the
pathogenesis of necrotising pneumonia and Labandeira-Rey
et al. could show in a mouse model that the PVL toxin alone
might be suﬃcient to cause pneumonia, it is not likely to be
theonlyvirulencedeterminantresponsibleforthissyndrome
[2, 22].
The outcome of patients with necrotizing pneumonia
may be poor in many cases even if appropriate antibiotics are
administered.Inaddition,intensivesupportivecareiscrucial
for improving the outcome in these severe infections [23].
In our patient, necrotizing pneumonia developed shortly
after incision of a Bartholin’s abscess. Infection of the
Bartholin’s gland is the most common infectious vulvar
disease and develops in approximately 2% of all women [24].
Surgical intervention is considered the primary treatment,
and controversy on the beneﬁt of antibiotics exists [25, 26].
Complicationratesareverylow,butcasesofsevereinfections
have been reported [27–36]. S. aureus appears to be only
very rarely involved in these cases. Clinical complications
have included septic shock, toxic-like-syndrome, necrotizing
fasciitis, myocarditis, and gangrene but pneumonia has not
been reported.
Bartholin’s abscesses mostly contain a mixed ﬂora of
aerobic and predominantly anaerobic bacteria. The most
frequently isolated aerobe is Escherichia coli, while S. aureus
is only rarely detected [37, 38].
PVL-positive S. aureus infection should early be included
in the diﬀerential diagnosis when young immunocompetent
persons develop necrotizing pneumonia. Various minor
infections—suchasBartholin’s abscess—canprecedethislife
threatening syndrome. Antibiotic treatment with bacterici-
dal antistaphylococcal agents is recommended, and invasive
surgical procedures may become necessary.
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